Protocol Ledger

NCT07218510 · Phase II · RECRUITING

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Interventional Phase II clinical trial protocol NCT07218510 sponsored by City of Hope in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-07 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07218510
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07218510
Protocol FieldVerified Registry Value
NCT IdentifierNCT07218510
Consolidated Lead SponsorCity of Hope
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2026-01-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for City of Hope across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI